Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

DAIICHI S : Notice on Details of the Share Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2011 | 04:20am EST
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)

Reference

Date of Board of Directors resolution: June 27, 2011

###
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
01/19 KITE PHARMA : Establishes a Strategic Partnership With Daiichi Sankyo to Develop..
01/18 DAIICHI SANKYO : Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1..
01/18 DAIICHI SANKYO : Announces Participation in the Global Initiative, Access Accele..
01/17 WON'T PURSUE STAKE SALE IN FORTIS : Ex-ranbaxy promoters assure hc
01/16 FORTIS HEALTHCARE : Daiichi moves hc to block fortis stake sale
01/12 DAIICHI SANKYO : Findings from Daiichi Sankyo in the Area of Immunoglobulins Rep..
01/11 DAIICHI SANKYO : Shuts india r&d arm
01/11 DAIICHI SANKYO : Shuts 170-man research unit
01/09 DAIICHI SANKYO : Announces Reorganization of Research & Development System
01/09 DAIICHI SANKYO : Establishes Strategic Partnership for Cellular Therapy Pipeline..
More news
Sector news : Pharmaceuticals - NEC
03:21p European shares ease ahead of Trump inauguration
12:20p Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/18 Daiichi launches Japan-based study of breast cancer candidate U3-1402
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
01/09 Kite Pharma signs deal with Daiichi Sankyo to commercialize lead product cand..
2016 FDA OKs Teva's generic version of blood pressure med Tribenzor
2016 6 Ways To Profit From This Looming Disaster
Advertisement
Financials ( JPY)
Sales 2017 928 677 M
EBIT 2017 -
Net income 2017 68 653 M
Finance 2017 298 760 M
Yield 2017 2,84%
P/E ratio 2017 23,71
P/E ratio 2018 25,23
EV / Sales 2017 1,56x
EV / Sales 2018 1,63x
Capitalization 1 747 713 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 2 360  JPY
Spread / Average Target -4,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..4.41%15 219
JOHNSON & JOHNSON-0.88%310 685
ROCHE HOLDING LTD.1.29%200 208
PFIZER INC.-2.40%192 367
NOVARTIS AG-3.71%185 489
MERCK & CO., INC.2.48%166 338
More Results